ライフサイエンスコーパス: bone biopsy

1 patients underwent (68)Ga-PSMA PET/CT before bone biopsy.

2 s was not obtained with initial percutaneous bone biopsy.

3 were DFO-positive and 6 were DFO-negative on bone biopsy.

4 mor percentage >= 30%) of (68)Ga-PSMA-guided bone biopsies.

5 Studies that have conducted bone biopsies after kidney transplantation are scarce, a

6 8.5 years; 82.3% had diabetes) who underwent bone biopsy after MR imaging for possible osteomyelitis

7 lt posttransplant patients agreed to undergo bone biopsies and blood drawings.

8 All underwent a percutaneous bone biopsy and an ulcer bed biopsy.

9 It was subsequently followed by bone biopsy and microbiological analysis (gold standard)

10 an be closed and osteomyelitis is present on bone biopsy, appropriate antibiotic therapy is reasonabl

11 tastasizes to bone, and analyses of DNA from bone biopsies are exceptionally challenging.

12 We obtained bone biopsies at the time of renal transplant and after

13 Additional sites for possible bone biopsy become apparent for exclusion of other diagn

14 ated to antibiotic treatment based on either bone biopsy cultures or ulcer bed biopsy cultures.

15 A small sample of 18 transilial bone biopsies did not show any qualitative abnormalities

16 Bone biopsies for mineralized bone histology were obtain

17 However, the success rate of CT-guided bone biopsies for molecular analyses in mPC patients is

18 ET/CT improves the success rate of CT-guided bone biopsies for molecular analyses, thereby identifyin

19 romising tool to improve the harvest rate of bone biopsies for molecular analyses.

20 rmine the success rate of (68)Ga-PSMA-guided bone biopsies for molecular diagnostics in mPC patients.

21 This 'liquid bone biopsy for FGF23 dynamics' enables large-scale long

22 ry and immunohistochemistry were compared on bone biopsies from 20 patients with ADPKD with a mean eG

23 tase expression in osteoblasts isolated from bone biopsies from 27 kidney transplant patients.

24 e compositional and mechanical properties of bone biopsies from bisphosphonate-treated patients with

25 In this case-control study, trabecular bone biopsies from iliac crest were collected intra-oper

26 on by denosumab (DMAb) and RNA-sequencing of bone biopsies from postmenopausal women to identify oste

27 set (SenMayo) and validate its enrichment in bone biopsies from two aged human cohorts.

28 h for the first time we mapped gadolinium in bone biopsy from a male patient with idiopathic osteopor

29 not achieving remission at 12 months in the bone biopsy group was 1.13; (95% CI 0.80-1.60) in the IT

30 The remission rate in the bone biopsy group was 31.4% (95% CI 18.1-48.7%) and 39.4

31 SMA PET/CT may be considered for guidance of bone biopsies in both clinical practice and clinical tri

32 The diagnosis of CRMO was based on bone biopsy in 9 patients and clinical course/laboratory

33 Percutaneous bone biopsy is the reference standard for guiding antibi

34 ive backscatter electron microscopy assessed bone biopsy outcomes in 22 participants.

35 This study found no evidence to recommend bone biopsies prior to the start of antibiotics in patie

36 pediatric peritoneal dialysis patients with bone biopsy-proven 2 degrees HPT.

37 Final analysis of bone biopsy results included tumor type, malignancy, fin

38 Human bone biopsies reveal normal bone formation in areas trea

39 e analysis compared gene expression in human bone biopsy samples taken from lumbar spine and iliac cr

40 nts in the area treated with rhBMP-2/ACS and bone biopsy samples were taken for histological analysis

41 reated mouse femur) and clinical DAR images (bone biopsy sections from (223)RaCl(2)-treated castratio

42 However, bone biopsies showed post-transplant impairment of trabe

43 still requires pathological evaluation of a bone biopsy specimen for definitive diagnosis and CT ima

44 D206(+)) macrophages were enriched in bmCRPC bone biopsy specimens compared with primary tumors or ly

45 d RANKL) and decreased osteoclastogenesis in bone biopsy specimens, as compared with control treatmen

46 ometric parameters determined by analysis of bone biopsy specimens.

47 We examined 51 bone-biopsy specimens obtained after a 3-year, double-bl

48 Twenty patients with CF had bone biopsies taken after double tetracycline labeling.

49 ycline-labeled histomorphometric analysis of bone biopsies taken at the time of liver transplantation

50 Specimens from bone biopsies (three patients) were examined.

51 ntitative computed tomography (HR-pQCT), and bone biopsies to evaluate changes in bone in the 32 eval

52 GF23 assays that can substitute for invasive bone biopsies to infer the activity of the three main st

53 A soft tissue and bone biopsy was performed and sent for histological exam

54 Bone biopsies were obtained 3 months and 4 years after i

55 calcitriol or doxercalciferol for 8 mo, when bone biopsies were repeated.

56 ns, radiography of the pelvis and hands, and bone biopsy were performed.